Order Article Reprints

Barra J, Cerda-Infante J, Sandoval L, Gajardo-Meneses P, Henriquez JF, Labarca M, Metz C, Venegas J, Retamal C, Oyanadel C, et al. D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy. Cancers. 2021; 13(14):3622. https://doi.org/10.3390/cancers13143622

Barra, Jonathan, Javier Cerda-Infante, Lisette Sandoval, Patricia Gajardo-Meneses, Jenny F. Henriquez, Mariana Labarca, Claudia Metz, Jaime Venegas, Claudio Retamal, Claudia Oyanadel, and et al. 2021. "D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy" Cancers 13, no. 14: 3622. https://doi.org/10.3390/cancers13143622

Barra, J., Cerda-Infante, J., Sandoval, L., Gajardo-Meneses, P., Henriquez, J. F., Labarca, M., Metz, C., Venegas, J., Retamal, C., Oyanadel, C., Cancino, J., Soza, A., Cuello, M. A., Roa, J. C., Montecinos, V. P., & Gonzalez, A. (2021). D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy. Cancers, 13(14), 3622. https://doi.org/10.3390/cancers13143622